Menstrual bleeding-specific quality of life in women on antiplatelet therapy
Background: Antiplatelet therapy may affect menstrual blood loss in women of reproductive age. Objectives: To determine menstrual bleeding and related quality of life (QoL) in women on antiplatelet therapy. Methods: We performed a cross-sectional study at a tertiary care center in the Netherlands, i...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Research and Practice in Thrombosis and Haemostasis |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2475037925002341 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399356323528704 |
|---|---|
| author | Eva K. Kempers Johanna A. van der Zande Paula M. Janssen Jérôme M.J. Cornette Jolien W. Roos–Hesselink Marieke J.H.A. Kruip |
| author_facet | Eva K. Kempers Johanna A. van der Zande Paula M. Janssen Jérôme M.J. Cornette Jolien W. Roos–Hesselink Marieke J.H.A. Kruip |
| author_sort | Eva K. Kempers |
| collection | DOAJ |
| description | Background: Antiplatelet therapy may affect menstrual blood loss in women of reproductive age. Objectives: To determine menstrual bleeding and related quality of life (QoL) in women on antiplatelet therapy. Methods: We performed a cross-sectional study at a tertiary care center in the Netherlands, including women on antiplatelet therapy with an active menstrual cycle and a control group of reproductive-aged women who did not use antiplatelets. Participants completed an online questionnaire containing 2 validated instruments: (1) the Menstrual Bleeding Questionnaire (MBQ) to measure menstrual bleeding-specific QoL, and (2) the Pictorial Blood Loss Assessment Chart (PBAC). Scaled MBQ scores range from 0 to 100, with higher scores indicating worse QoL. A PBAC score of 100 is generally considered indicative of heavy menstrual bleeding. Results: In total, 38 women prescribed antiplatelet drugs (median age, 44 years [IQR, 40-48]) and 100 control women (median age, 35 years [IQR, 27-43]) completed the study questionnaire. Most common indication for antiplatelet therapy was stroke/transient ischemic attack (26%). Acetylsalicylic acid/carbasalate calcium (50%) and clopidogrel (37%) were most frequently used. Mean (SD) scaled MBQ scores were 18.9 (11.2) among antiplatelet drug users and 22.4 (10.9) in control women (adjusted mean difference, −3.28 [95% CI, −7.90, 1.35]). Median PBAC scores were 101.5 (IQR, 50.5-207) and 96.0 (IQR, 73.0-174.8; adjusted mean ratio, 0.784 [95% CI, 0.521, 1.18]), respectively. A PBAC score >100 was reported in 37% and 36% of the antiplatelet and control groups, respectively. Conclusion: Menstrual bleeding-specific QoL was comparable between women on antiplatelet therapy and controls, although controls experienced a high burden of menstrual bleeding-related complaints. Menstrual blood loss did not seem to be increased. |
| format | Article |
| id | doaj-art-a86934cd23df4a4db03bdf01b4e8f7e9 |
| institution | Kabale University |
| issn | 2475-0379 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Research and Practice in Thrombosis and Haemostasis |
| spelling | doaj-art-a86934cd23df4a4db03bdf01b4e8f7e92025-08-20T03:38:19ZengElsevierResearch and Practice in Thrombosis and Haemostasis2475-03792025-05-019410291010.1016/j.rpth.2025.102910Menstrual bleeding-specific quality of life in women on antiplatelet therapyEva K. Kempers0Johanna A. van der Zande1Paula M. Janssen2Jérôme M.J. Cornette3Jolien W. Roos–Hesselink4Marieke J.H.A. Kruip5Department of Hematology, Erasmus University Medical Center Rotterdam, Rotterdam, the NetherlandsDepartment of Cardiology, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, the NetherlandsDepartment of Neurology, Erasmus University Medical Center, Rotterdam, the NetherlandsDepartment of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, the NetherlandsDepartment of Cardiology, Erasmus University Medical Center, Rotterdam, the NetherlandsDepartment of Hematology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Correspondence Marieke J. H. A. Kruip, Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.Background: Antiplatelet therapy may affect menstrual blood loss in women of reproductive age. Objectives: To determine menstrual bleeding and related quality of life (QoL) in women on antiplatelet therapy. Methods: We performed a cross-sectional study at a tertiary care center in the Netherlands, including women on antiplatelet therapy with an active menstrual cycle and a control group of reproductive-aged women who did not use antiplatelets. Participants completed an online questionnaire containing 2 validated instruments: (1) the Menstrual Bleeding Questionnaire (MBQ) to measure menstrual bleeding-specific QoL, and (2) the Pictorial Blood Loss Assessment Chart (PBAC). Scaled MBQ scores range from 0 to 100, with higher scores indicating worse QoL. A PBAC score of 100 is generally considered indicative of heavy menstrual bleeding. Results: In total, 38 women prescribed antiplatelet drugs (median age, 44 years [IQR, 40-48]) and 100 control women (median age, 35 years [IQR, 27-43]) completed the study questionnaire. Most common indication for antiplatelet therapy was stroke/transient ischemic attack (26%). Acetylsalicylic acid/carbasalate calcium (50%) and clopidogrel (37%) were most frequently used. Mean (SD) scaled MBQ scores were 18.9 (11.2) among antiplatelet drug users and 22.4 (10.9) in control women (adjusted mean difference, −3.28 [95% CI, −7.90, 1.35]). Median PBAC scores were 101.5 (IQR, 50.5-207) and 96.0 (IQR, 73.0-174.8; adjusted mean ratio, 0.784 [95% CI, 0.521, 1.18]), respectively. A PBAC score >100 was reported in 37% and 36% of the antiplatelet and control groups, respectively. Conclusion: Menstrual bleeding-specific QoL was comparable between women on antiplatelet therapy and controls, although controls experienced a high burden of menstrual bleeding-related complaints. Menstrual blood loss did not seem to be increased.http://www.sciencedirect.com/science/article/pii/S2475037925002341aspirinclopidogrelcross-sectional studiesmenorrhagiaplatelet aggregation inhibitorsquality of life |
| spellingShingle | Eva K. Kempers Johanna A. van der Zande Paula M. Janssen Jérôme M.J. Cornette Jolien W. Roos–Hesselink Marieke J.H.A. Kruip Menstrual bleeding-specific quality of life in women on antiplatelet therapy Research and Practice in Thrombosis and Haemostasis aspirin clopidogrel cross-sectional studies menorrhagia platelet aggregation inhibitors quality of life |
| title | Menstrual bleeding-specific quality of life in women on antiplatelet therapy |
| title_full | Menstrual bleeding-specific quality of life in women on antiplatelet therapy |
| title_fullStr | Menstrual bleeding-specific quality of life in women on antiplatelet therapy |
| title_full_unstemmed | Menstrual bleeding-specific quality of life in women on antiplatelet therapy |
| title_short | Menstrual bleeding-specific quality of life in women on antiplatelet therapy |
| title_sort | menstrual bleeding specific quality of life in women on antiplatelet therapy |
| topic | aspirin clopidogrel cross-sectional studies menorrhagia platelet aggregation inhibitors quality of life |
| url | http://www.sciencedirect.com/science/article/pii/S2475037925002341 |
| work_keys_str_mv | AT evakkempers menstrualbleedingspecificqualityoflifeinwomenonantiplatelettherapy AT johannaavanderzande menstrualbleedingspecificqualityoflifeinwomenonantiplatelettherapy AT paulamjanssen menstrualbleedingspecificqualityoflifeinwomenonantiplatelettherapy AT jeromemjcornette menstrualbleedingspecificqualityoflifeinwomenonantiplatelettherapy AT jolienwrooshesselink menstrualbleedingspecificqualityoflifeinwomenonantiplatelettherapy AT mariekejhakruip menstrualbleedingspecificqualityoflifeinwomenonantiplatelettherapy |